Search Videos and More
News
Survival Similar for Younger and Older Patients with Metastatic Colorectal Cancer, Study Finds
Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study by Dana-Farber Cancer Institute investigators.
News
Immunotherapy May Yield Longer Treatment-Free Survival than Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Analysis uses novel endpoint of treatment-free survival (TFS) to ‘better balance the efficacy and toxicity to patients’
News
Finding New Targets for Acute Myeloid Leukemia in Children
Looking for genes AML needs for everyday survival turned up two strong ‘hits’ to pursue for therapeutic development.
Video
Rare Cancer: A Father's Journey with Medullary Kidney Cancer
A father and Air Force recruiter details his journey at Dana-Farber Cancer Institute with medullary kidney cancer - a rare cancer disproportionately affecting African Americans.
News
Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer
Dana-Farber Brigham Cancer Center is launching a new program designed to address the unique needs of women diagnosed with the earliest form of breast cancer. Nearly 60,000 women in the United States this year will be diagnosed with Ductal carcinoma in situ (DCIS), a type of breast cancer in which cancerous cells grow but are confined within the milk duct of the breast. The new program will offer DCIS patients outstanding clinical care delivered by Dana-Farber Brigham Cancer Center experts and will be the only such program in Greater Boston offering patients access to clinical trials specific to DCIS.
News
Researchers Solve Mystery of Retinoic Acid’s Potency Against High-Risk Neuroblastoma
For decades, retinoic acid has been a key part of the arsenal against the childhood cancer neuroblastoma. For just as long, scientists have wondered exactly how it works.
News
Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
Podcast Program
Unraveled
Podcast
Season 1, Episode 6: Dana-Farber in the Time of COVID
A beauty… that in some cases becomes tragic. It's not the way most people would describe a virus. In the simplest of terms, a virus is a snippet of genetic code. It can't reproduce on its own. In order to replicate, it needs to infect and hijack a living cell.
News
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes
Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
News
In Memoriam: David Morse Livingston, MD, Renowned Scientist and Esteemed Mentor
Dana-Farber mourns the loss of David Morse Livingston, MD, renowned scientist and esteemed mentor who not only made key discoveries, but also forged novel collaborations that opened new paths in cancer science.
News
New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain Cancer
Researchers at Dana-Farber Cancer Institute and MIT have developed a new way to determine whether individual patients will respond to a specific cancer drug or not.